Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck    LUN   DK0010287234

H. LUNDBECK (LUN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
12/07/2017 12/08/2017 12/11/2017 12/12/2017 12/13/2017 Date
300.9(c) 303.9(c) 302.7(c) 307.1(c) 305 Last
432 165 261 926 303 338 337 937 413 493 Volume
+0.10% +1.00% -0.39% +1.45% -0.68% Change
More quotes
Financials ( DKK)
Sales 2017 17 262 M
EBIT 2017 4 498 M
Net income 2017 2 708 M
Finance 2017 3 295 M
Yield 2017 2,33%
Sales 2018 18 065 M
EBIT 2018 4 996 M
Net income 2018 3 229 M
Finance 2018 5 459 M
Yield 2018 3,46%
P/E ratio 2017 22,44
P/E ratio 2018 19,21
EV / Sales2017 3,35x
EV / Sales2018 3,08x
Capitalization 61 128 M
More Financials
Company
H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders.It operates through the following geographical segments: Europe, the Unites States of America, and International Markets.Its product portfolio... 
Sector
Pharmaceuticals
Calendar
02/07Earnings Release
More about the company
Surperformance© ratings of H. Lundbeck
Trading Rating : Investor Rating :
More Ratings
Latest news on H. LUNDBECK
12/05 H LUNDBECK : Lundbecks Brintellix approved in China
12/04 H LUNDBECK : Lundbeck's Brintellix approved in China
12/04 LUNDBECK’S BRINTELLIX APPROVED : Brintellix is now approved for the treatm..
12/02 H LUNDBECK : Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LG..
11/23 H LUNDBECK : Lundbeck increases its share capital by 116,330 shares as a result ..
11/22 H LUNDBECK : Transactions with shares and linked securities in H. Lundbeck A/S m..
11/21 ACORDA THERAPEUTICS : Announces Royalty Monetization Transactions for $53 Millio..
11/21 H LUNDBECK : New Findings from H. Lundbeck A/S in the Area of Clobazam Therapy D..
11/21 H LUNDBECK : Transactions with shares and linked securities in H. Lundbeck AS ma..
11/21 H LUNDBECK : Lundbeck increases its share capital by 116,330 shares (0.0585 % of..
More news
Sector news : Pharmaceuticals - NEC
12:13p REGENERON PHARMACEUTICALS : France's Sanofi pins hopes on new drugs after setbac..
10:09aDJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
09:55aDJSANOFI : to Begin at Least 10 Phase 3 Studies Over Next 12 Months
06:47a SANOFI : Did Sanofi, WHO ignore warning signals on dengue vaccine?
12/12 Sanofi investors hungry for drug progress and deal news
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/08 H. Lundbeck A/S ADR 2017 Q3 - Results - Earnings Call Slides
11/08 H. Lundbeck A/S reports Q3 results
11/02 YOUR DAILY PHARMA SCOOP : Teva Q3 Results, Boost For RedHill, Clovis Reports Rub..
11/01 Otsuka and Lundbeck not quite there with brexpiprazole in Alzheimer's-related..
09/18 TEVA PHARMACEUTICAL : An Opportunity Or A Falling Knife? (Part 2)
Chart H. LUNDBECK
Duration : Period :
H. Lundbeck Technical Analysis Chart | LUN | DK0010287234 | 4-Traders
Technical analysis trends H. LUNDBECK
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 16
Average target price 315  DKK
Spread / Average Target 2,4%
EPS Revisions
Managers
NameTitle
Anders Götzsche Executive VP, Chief Executive & Financial Officer
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Anders Gersel Pedersen Executive Vice President-Research & Development
Jørn Møller Mayntzhusen Director & Senior Manager-Supply Optimisation
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK5.36%9 533
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659